These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1267559)

  • 21. [On treatment trials of hemophiliacs with epsilon-aminocaproic acid (Epsamon)].
    Fonio A
    Schweiz Med Wochenschr; 1966 Dec; 96(51):1723-6. PubMed ID: 5973382
    [No Abstract]   [Full Text] [Related]  

  • 22. Coagulation abnormalities in type 1 Gaucher disease in children.
    Deghady A; Marzouk I; El-Shayeb A; Wali Y
    Pediatr Hematol Oncol; 2006; 23(5):411-7. PubMed ID: 16728361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B.
    Goldenberg NA; Bombardier C; Hathaway WE; McFarland K; Jacobson L; Manco-Johnson MJ
    Haemophilia; 2008 Jan; 14(1):68-77. PubMed ID: 18005147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs.
    Carmassi F; Giannarelli C; De Giorgi A; De Negri F
    Haemophilia; 2007 Jan; 13(1):106-7. PubMed ID: 17212735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance of factor IX analysis in blood coagulation tests].
    Kakishita E; Nishida Y
    Nihon Rinsho; 1989 Dec; 48 Suppl():834-6. PubMed ID: 2622013
    [No Abstract]   [Full Text] [Related]  

  • 27. Aggregation of red blood cells in patients with Gaucher disease.
    Adar T; Ben-Ami R; Elstein D; Zimran A; Berliner S; Yedgar S; Barshtein G
    Br J Haematol; 2006 Aug; 134(4):432-7. PubMed ID: 16827817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis.
    Taylor SA; Duffin J; Cameron C; Teitel J; Garvey B; Lillicrap DP
    Thromb Haemost; 1992 Jan; 67(1):63-5. PubMed ID: 1615485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Congenital deficiency of plasma thromboplastin component (PTC-factor IX): report of 25 cases from 19 unrelated families.
    Agarwal MB; Mehta BC
    J Assoc Physicians India; 1982 Jan; 30(1):17-9. PubMed ID: 6820363
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
    Brandt JT; Arkin CF; Bovill EG; Rock WA; Triplett DA
    Arch Pathol Lab Med; 1990 Feb; 114(2):135-41. PubMed ID: 2405809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A quantitative two-stage assay for factor IX (Christmas factor) using plasma from dogs with Christmas disease.
    Aronson DL; Dodds WJ; Mustafa AJ
    Thromb Diath Haemorrh; 1972 Jul; 27(3):529-34. PubMed ID: 4662614
    [No Abstract]   [Full Text] [Related]  

  • 33. Unintended benefit of anabolic steroid use in hemophilia B leiden.
    Rimmer EK; Seftel MD; Israels SJ; Houston DS
    Am J Hematol; 2012 Jan; 87(1):122-3. PubMed ID: 22038733
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia.
    Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD
    Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Blood platelets of hemophilia patients].
    Weibbbach G; Bührdel P; Domula M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1973; 100(1):131-43. PubMed ID: 4128511
    [No Abstract]   [Full Text] [Related]  

  • 37. [Dentition restoration in hemophilia under substitution of AHG concentrates].
    Tetsch P; Esser E
    Dtsch Zahnarztl Z; 1972 May; 27(5):399-404. PubMed ID: 4112700
    [No Abstract]   [Full Text] [Related]  

  • 38. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure and function of factor IX: defects in haemophilia B.
    McGraw RA; Davis LM; Lundblad RL; Stafford DW; Roberts HR
    Clin Haematol; 1985 Jun; 14(2):359-83. PubMed ID: 3899439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.